Efficacy of inhaled hydrogen on neurological outcome following brain ischaemia during post-cardiac arrest care (HYBRID II): a multi-centre, randomised, double-blind, placebo-controlled trial.
Tomoyoshi Tamura, Masaru Suzuki, Koichiro Homma, Motoaki Sano · EClinicalMedicine · 2023
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 429 patients, the increase in participants with good neurological outcomes following post-OHCA H₂ inhalation in a selected population of patients was not statistically significant. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in 429 patients. The increase in participants with good neurological outcomes following post-OHCA H₂ inhalation in a selected population of patients was not statistically significant.
What the Researchers Studied
The researchers studied 429 patients. The study used a randomized, double-blind, placebo-controlled human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
2% inhaled H₂ concentration. The increase in participants with good neurological outcomes following post-OHCA H₂ inhalation in a selected population of patients was not statistically significant. The authors concluded that however, the secondary outcomes suggest that H₂ inhalation may increase 90-day survival without neurological deficits.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, double-blind, placebo-controlled human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 429 patients. The reported sample size was 429. The study used a randomized, double-blind, placebo-controlled human clinical trial. The hydrogen delivery method was inhaled hydrogen gas. The reported hydrogen concentration was 2% inhaled H₂ concentration.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.